Acrivon Therapeutics appoints Ivana Magovcevic-Liebisch, Ph.D., J.D., to board of directors

Acrivon Therapeutics, Inc.

Appointment effective February 8, 2024; she will receive 32,500 stock options vesting over 3 years.
Dr. Magovcevic-Liebisch is President and CEO of Vigil Neuroscience and brings 25+ years of industry experience.
She will enter into standard indemnification agreement and receive cash compensation per non-employee director policy.
No arrangements or transactions requiring disclosure under Item 404(a) exist with her selection.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ivana Magovcevic-Liebisch

Director

ACRV · Acrivon Therapeutics, Inc.

Effective: 2024-02-08
Filed: February 8, 2024, 6:59 PM ET

On February 7, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Ivana Magovcevic-Liebisch, Ph.D., J.D., as a director of the Company, effective February 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ivana Magovcevic-Liebisch was appointed as Director at Acrivon Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 7, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Ivana Magovcevic-Liebisch, Ph.D., J.D., as a director of the Company, effective February 8, 2024.

View on SEC.gov

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-027629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.